Submit CV Hire Talent

Boston · In-House Regulatory Counsel Recruiting

Medtech Regulatory Counsel Recruiters in Boston, Massachusetts

A general counsel hiring medtech regulatory counsel in Boston needs a lawyer who can clear QMSR and PMA client walls across the Marlborough–Acton–Andover plants, not a commercial device counsel who has never sat an inspection.

Discuss a mandate
›Boston medtech regulatory counsel hires fail on QMSR and PMA client walls, not on empty pipelines.

Boston's 19 closed in-house regulatory counsel searches Sartori completed over three years turned on QMSR and PMA client walls, not on empty pipelines. Sartori & Partners is highly technical in In-House Regulatory Counsel Recruiting work in Boston with those 19 engagements. We find across 250 structured interviews with Boston partners that a lawyer already behind a competitor's inspection file cannot sit another manufacturer's Quality Review Board. That wall is the product we hire against.

01 — The brief answer

What medtech regulatory counsel recruiters Boston underwrite on client walls

From the ~3,500 lawyers we map in Boston, device-regulatory client walls across Marlborough, Acton, Andover and Raynham decide who can join an in-house Quality Review Board. Boston Scientific, Hologic, Insulet, Smith & Nephew and Johnson & Johnson sit inside the same west-and-south corridor; the client-wall geometry among those plants is the hiring problem. A lawyer who has already advised a competitor's PMA, 510(k) or inspection response cannot walk into another manufacturer's QMSR file. Companies searching for medtech regulatory counsel recruiters Boston usually call us once a commercial-counsel shortlist has already hit that wall.

One general counsel at a listed device manufacturer told us that a candidate who had already advised a competitor's PMA could not sit on her Quality Review Board. FDA's Quality Management System Regulation took effect on 2 February 2026, replacing QSIT with a risk-based inspection that reaches management reviews, internal audits and supplier audits. That is in-house work, not a firm secondment. For 8 years Sartori has run Boston in-house regulatory counsel files for device-manufacturer general counsel and heads of legal in Healthcare & Life Sciences. Our Boston In-House Regulatory Counsel Recruiting telemetry over three years records 19 closed searches, a 94 percent completion rate, and a median 8-to-16-week fill.

Boston device-regulatory client walls, not resume volume, decide who can join a Quality Review Board. Johnson & Johnson still lists a Raynham Sr. Director, Regulatory Law, Orthopedics seat posted 4 May 2026.

Years in this market

8years

Searches closed · 3 yrs

19

Completion rate

94%

Median timeline

8to 16 weeks

Sartori & Partners trailing record · In-House Regulatory Counsel Recruiting · Boston

02 — The bench

Medtech regulatory legal recruitment: the bench that can clear QMSR walls

In 12 closed in-house searches in Boston over 24 months, 4 stalled after we shortlisted commercial device counsel whose QMSR walls would not clear. We misjudge the seat when a commercial-counsel title is treated as enough. In 12 closed in-house searches in Boston over 24 months, 8 offers went to lawyers already counseling a Massachusetts device manufacturer, Sartori's mandate telemetry shows. A chief legal officer at a west-corridor implant company said the seat needed someone who had already lived through a QMSR inspection, not a commercial contract book.

The hireable skill signature is in-house regulatory counsel who has already sat 510(k) or PMA filings, FDA inspections, post-market data, field actions and a Quality Review Board. Adjacent feeder seats are FDA life-sciences firm practice, in-house quality counsel, commercial device counsel and clinical contracting. A general counsel who briefs a commercial search will see CVs that cannot open an inspection folder.

Day to day the seat advises study start-up, audits, 510(k) and PMA and EU MDR/IVDR filings, advertising risk, field actions, and QMSR and ISO 13485 alignment. Johnson & Johnson's Raynham director seat, posted 4 May 2026, adds Orthopedics separation work inside 18 to 24 months. Our Boston mandate telemetry on this line still records a 27 percent counter-offer incidence because several plants pull the same in-house bench.

03 — Selected engagements

Recent in-house regulatory counsel recruiting work in Boston

Anonymised mandates from our Boston book — profile, complication and outcome. Select an engagement to open its file.

BOSTON × IN-HOUSE REGULATORY COUNSEL RECRUITING 3 ENGAGEMENTS · ANONYMISED

QMSR in-house counsel when the shortlist was all commercial device lawyers

A listed medical-device manufacturer with a west-of-Boston plant and a live FDA inspection calendar

Mandate
Confidential search for in-house regulatory counsel to own QMSR inspections, supplier audits and the Quality Review Board, reporting to the general counsel
Complication
Four of six longlisted CVs were commercial device counsel with no verified inspection file; one process stalled three weeks while we rebuilt from in-house quality counsel
Outcome
Hired an in-house quality-and-regulatory counsel from another Massachusetts device plant; offer accepted in 15 working days; no counter-offer

Premarket regulatory counsel against a PMA client wall

A PE-backed implant platform with a pending 510(k) and a notified-body file

Mandate
In-house regulatory counsel for 510(k) and PMA work, study start-up and post-market data, reporting to the chief legal officer
Complication
A finalist had advised a competitor's PMA at a prior firm; the wall did not clear; 27 percent counter-offer risk from a neighboring plant
Outcome
Placed in-house regulatory counsel who had sat a PMA at a non-competing device class; accepted after 14 working days

Spin-out regulatory lead before the Orthopedics separation clock

A multi-campus device group planning an 18-to-24-month Orthopedics separation

Mandate
In-house regulatory lead for FDA, EU MDR/IVDR, inspections, field actions and deal diligence on the Massachusetts campus
Complication
Temporary walls across the remaining MedTech book blocked two of five approached lawyers before first interview
Outcome
Hired a head of legal deputy who had already run a field-action file; 11-week fill

04 — The local market

Why in-house counsel recruiters Boston brief west-corridor device plants

Massachusetts recorded 10.6 thousand medical-equipment manufacturing jobs in December 2025. Those plants — not a downtown corporate-counsel hub — are why in-house regulatory headcount follows Marlborough, Acton, Andover and Raynham, per FRED's December 2025 series. Insulet's Form 10-K for the year ended 31 December 2025 recorded 5,400 full-time employees, a 38 percent increase over the prior year, and a 350,000 square-foot Acton headquarters that also houses U.S. manufacturing. About 60 percent of that headcount sat in the United States. MassMEDIC remains the New England healthtech membership body. Named operators on the same map include Boston Scientific and Hologic in Marlborough, Smith & Nephew in Andover, Johnson & Johnson MedTech in Raynham, Flagship Pioneering in Cambridge, and Haemonetics in Boston.

FDA's QMSR took effect on 2 February 2026 and replaced the 1997-era QS regulation, incorporating ISO 13485:2016 by reference. A head of legal recruiting at a Cambridge life-sciences operator reported to us that two of four finalists withdrew when the client wall on a pending field action would not clear. From the ~3,500 lawyers we map in Boston we watch coverage of device in-house regulatory seats. Our Boston mandate telemetry still records a 27 percent counter-offer incidence on this in-house line because several plants pull the same bench.

Hiring in Boston?

We map this market every day.

The market intelligence on this page is the same coverage we use to run retained in-house regulatory counsel recruiting mandates in Boston.

Discuss a Boston mandate→Candidates: speak confidentially→

[email protected]

05 — Mandates we run

Three in-house mandate types on Boston device-regulatory files

Sartori's Boston mandate telemetry over three years closed 19 In-House Regulatory Counsel Recruiting searches: 7 for QMSR and quality-system in-house counsel, 8 for premarket, clinical and post-market regulatory counsel, and 4 for acquisition-integration or spin-out regulatory leads. Our median time-to-fill on those files sat inside 8 to 16 weeks. Our median offer-to-acceptance on these Boston files is 15 working days. Our counter-offer incidence on the same line was 27 percent. A general counsel briefing this work is buying one of those three mandate shapes, not a generic in-house search.

  • QMSR and quality-system in-house counsel: inspection readiness after 2 February 2026, supplier audits, ISO 13485 alignment. Complication: a commercial-counsel CV that has never sat a management-review inspection.
  • Premarket, clinical and post-market regulatory counsel: 510(k), PMA, EU MDR/IVDR, study start-up, post-market data. Complication: prior firm advice on a competitor's filing that walls the candidate out of the Quality Review Board.
  • Acquisition-integration or spin-out regulatory lead: diligence and evidence integration, including Orthopedics separation work that Johnson & Johnson timed at 18 to 24 months on the Raynham posting of 4 May 2026. Complication: temporary walls across the remaining MedTech book.

06 — Compensation

Disclosed 2026 bands for medtech regulatory counsel jobs Boston

Two 2026 employer postings disclosed Massachusetts-listed medtech regulatory legal ranges. Johnson & Johnson's Sr. Director, Regulatory Law, Orthopedics posting, posted 4 May 2026 with Raynham among the listed bases, stated an anticipated base of $178,000–$307,050 and long-term incentive eligibility. Flagship Pioneering's Director/Senior Director, Regulatory Counsel seat in Cambridge stated a salary range of $172,000–$280,500, plus an annual incentive program and retirement benefits, with medical-device regulatory work inside the mandate. Neither posting split the range by Massachusetts site alone. The package shape is base plus bonus eligibility, LTIP or annual incentive, and retirement; notice periods were not published.

EmployerSeatDisclosed baseYear
Johnson & JohnsonSr. Director, Regulatory Law, Orthopedics (Raynham)$178,000–$307,050 plus LTIPMay 2026
Flagship PioneeringDirector/Senior Director, Regulatory Counsel (Cambridge)$172,000–$280,500 plus annual incentive2026

Johnson & Johnson disclosed a $178,000–$307,050 base for the Raynham regulatory-law director seat in May 2026. Across the 19 In-House Regulatory Counsel Recruiting searches Sartori closed in Boston over three years, counter-offers still hit 27 percent once a written range sat on the table. Our median offer-to-acceptance on those files was 15 working days.

07 — Methodology

How Sartori reads the Boston medtech regulatory counsel market

  1. 01 — BriefMandate, success profile and conflicts frame agreed in writing.
  2. 02 — Market mapThe live universe mapped from our coverage, not whoever is in motion.
  3. 03 — ApproachConfidential, principal-led conversations with the mapped shortlist.
  4. 04 — ShortlistUnderwritten candidates presented with evidence, not CVs.
  5. 05 — OfferPackage design, references and counter-offer defence.
  6. 06 — CloseResignation, notice and the first hundred days, managed.

Median 8 to 16 weeks from signed brief to accepted offer on closed Boston mandates.

Sartori & Partners runs a continuous research program over nearly 1.5 million lawyer profiles mapped globally, tens of thousands of structured candidate and client interviews, thousands of mandate records, and quarterly market surveys running since 2019. Across 250 structured interviews with Boston in-house counsel in the 24 months to August 2026, our research shows 38% said their regulatory remit widened after a QMSR inspection or a device acquisition. Of 250 interviews, 71 involved lawyers who had moved from private-practice FDA or device regulatory work in the previous three years, our Boston files show. From the ~3,500 lawyers we map in Boston we watch coverage of device in-house regulatory seats. We cannot see the inspection file a candidate sat behind at a competitor until that company's conflicts counsel writes the wall.

Public inputs we used are FRED's December 2025 medical-equipment series, Insulet's year-end 2025 Form 10-K, FDA QMSR guidance as reported by Exponent in 2026, Johnson & Johnson's 4 May 2026 Raynham posting, and Flagship's Cambridge Regulatory Counsel listing. Our mandate telemetry is 19 closed In-House Regulatory Counsel Recruiting searches over three years in Boston, with our 27 percent counter-offer incidence and 15-working-day median offer-to-acceptance window read from those files.

Hiring in Boston?

Brief us on the search.

Whether you are building a team or weighing a move, we listen first. No obligation.

Hire legal talent Submit your CV

[email protected]

08 — Sources

Market sources for this page

›6 sources cited on this page
  1. 1Sartori & Partners — Boston Legal Talent Research Programme (250 structured interviews; ~3,500 lawyers mapped; quarterly surveys since 2019; mandate telemetry)Boston mapping (~3,500); 250 structured interviews; 19 closed In-House Regulatory Counsel Recruiting searches; 94 percent completion; 8-to-16-week median; 27 percent counter-offer; 15-working-day offer-to-acceptance; 12-search stall and incumbent-offer reads; 38 percent remit-widening; 71 private-practice movers; QMSR wall testimony
  2. 2Sr. Director, Regulatory Law, Orthopedics, Raynham / New Brunswick / West Chester | Johnson & Johnson CareersRaynham-listed Sr. Director, Regulatory Law, Orthopedics seat posted 4 May 2026; anticipated base $178,000–$307,050; LTIP eligibility; 18-to-24-month Orthopedics separation
  3. 3Director/Senior Director, Regulatory Counsel at Flagship Pioneering, Inc.Cambridge Regulatory Counsel seat; salary range $172,000–$280,500; annual incentive and retirement; medical-device regulatory work in the mandate
  4. 4FDA’s Quality Management System Regulation for Medical Devices | ExponentQMSR effective 2 February 2026; ISO 13485:2016 incorporated by reference; QSIT replaced; 1997-era QS regulation superseded
  5. 5All Employees: Manufacturing: Durable Goods: Medical Equipment and Supplies Manufacturing in Massachusetts (SMU25000003133910001) | FRED | St. Louis FedMassachusetts medical equipment and supplies manufacturing employment of 10.6 thousand persons in December 2025
  6. 6Insulet details Omnipod growth and global risks | PODD Annual Report (10-K)Insulet 5,400 full-time employees as of 31 December 2025; 38 percent year-on-year increase; 350,000 sq ft Acton HQ and U.S. plant; about 60 percent of headcount in the United States

09 — Questions

In-House Regulatory Counsel Recruiting in Boston — common questions

Who are the best medtech regulatory counsel recruiters in Boston?

There is no audited league table for medtech regulatory counsel recruiters in Boston. Judge instead on how much of the market a firm maps and what it has closed. Sartori & Partners maps roughly 3,500 lawyers in Boston and has worked this market for 8 years. Over the trailing three years we closed 19 in-house regulatory counsel recruiting searches here at a 94% completion rate, with a median timeline of 8 to 16 weeks. Across 250 structured interviews with Boston in-house counsel in the 24 months to August 2026, our research shows 38% said their regulatory remit widened after a QMSR inspection or a device acquisition. One general counsel at a listed device manufacturer told us that a candidate who had already advised a competitor's PMA could not sit on her Quality Review Board. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.

Why do general counsel brief medtech regulatory counsel recruiters Boston rather than a commercial-counsel search?

Because 4 of 12 closed Boston in-house searches over 24 months stalled on QMSR client walls after a commercial-counsel shortlist. The hireable CV has already sat an inspection, a 510(k) or PMA, and a Quality Review Board. Commercial device counsel sitting outside Massachusetts is the wrong feeder.

How long does a Boston in-house medtech regulatory counsel search take?

Typical Sartori mandates on this line close in 8 to 16 weeks, with a 15-working-day median offer-to-acceptance. Counter-offers hit 27 percent on our Boston in-house regulatory files. QMSR and PMA walls add a conflicts-clearance week before the first approach.

What does Boston medtech regulatory counsel actually do day to day?

The seat runs QMSR inspections after 2 February 2026, 510(k) and PMA filings, study start-up, field actions and Quality Review Boards. Adjacent feeders are FDA firm practice, in-house quality counsel and clinical contracting. A chief legal officer is buying inspection and evidence work, not a commercial contract book.

What did employers disclose for Boston medtech regulatory legal pay in 2026?

Johnson & Johnson posted $178,000–$307,050 plus LTIP for the Raynham regulatory-law director seat on 4 May 2026. Flagship Pioneering listed $172,000–$280,500 plus annual incentive for Cambridge Regulatory Counsel. Neither posting split the range by Massachusetts site alone.

Which west-corridor employers hire this in-house regulatory seat?

At least six named device and life-sciences operators sit on the Boston medtech regulatory map in 2026. Boston Scientific, Hologic, Insulet, Smith & Nephew, Johnson & Johnson and Flagship Pioneering all need QMSR, PMA or device-regulatory counsel. That briefing belongs to a general counsel or head of legal.

Why brief this hire in 2026 rather than wait?

FDA's QMSR took effect on 2 February 2026, and Johnson & Johnson still lists a Raynham regulatory-law director seat with an 18-to-24-month Orthopedics separation. Insulet's Acton plant ended 2025 with 5,400 employees and a 38 percent headcount rise. Inspection and spin-out files will not wait for a commercial-counsel restaff.

Related

Where to go next

In-house & general counsel · All services · Locations · Practice areas